Anti-Covid pills manufactured in India for severe cases of Covid-19 to be rolled out soon for public
Molnupiravir, a Merck drug which is an orally ingested antiviral medicine to be used in an emergency for treating adults who are probably progressing towards severe infection of COVID-19 from a moderate infection or need to be hospitalised.
The Chairman of Covid Strategy Group, Dr Ram Vishwakarma, informed NDTV on Wednesday that another Pharma company Pfizer has also come up with a pill to be used against the severity of COVID-19 called Paxlovid.
He further added that the authorisation for the use of the Merck drug Molnupiravir is likely within a few number of days, while the Pfizer drug Paxlovid may be needing some more time to get authorised.
According to Dr Vishwakarma, both the drugs on public usage will definitely make a difference far more than the vaccines already used by the government in the drive against COVID-19.
He further added that these drugs would be very effective in reducing the pandemic to an endemic in the initial stage, later on, will be the last nail in the coffin of the COVID-19 Virus.
He added that Five major pharmaceutical companies are now in coordination with the drug manufacture resulting in quicker production of the drug Molnupiravir for which the approval is expected any day now.
The Merck drug data is already placed before the regulators, and hopefully, the approval will be quick, hence most probably, within a month, the decision will be finalised.
Officials of the pharmaceutical company Pfizer have claimed that their drug Paxlovid will definitely reduce the risk of vulnerability to the infection, being hospitalised or ending up dead by 89 per cent in the case of vulnerable adults.
Pfizer further stated that clinical trials have already been conducted on the usage of Paxlovid with amazing results.
Pfizer will have to use Indian facilities for large scale manufacturing of Paxlovid since it will reduce the price significantly than the expected price of $700 if manufactured elsewhere.
Dr Vishwakarma said that if the government of India would be involved in manufacturing, the cost of the drug, which initially would be around Rs. Four thousand per cycle of dosage, then it could be lowered from Rs. 500 to Rs. 1000 only, which will be highly beneficial to the general public when the government use this drug in the drive against COVID-19.